| 000 | 01780 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515041413.0 | ||
| 264 | 0 | _c20070111 | |
| 008 | 200701s 0 0 eng d | ||
| 022 | _a1551-4005 | ||
| 024 | 7 |
_a10.4161/cc.5.19.3255 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarter, Bing Z | |
| 245 | 0 | 0 |
_aRegulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. _h[electronic resource] |
| 260 |
_bCell cycle (Georgetown, Tex.) _cOct 2006 |
||
| 300 |
_a2223-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aBlast Crisis |
| 650 | 0 | 4 | _aCell Cycle |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aKinesins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 700 | 1 | _aMak, Duncan H | |
| 700 | 1 | _aShi, Yuexi | |
| 700 | 1 | _aSchober, Wendy D | |
| 700 | 1 | _aWang, Rui-Yu | |
| 700 | 1 | _aKonopleva, Marina | |
| 700 | 1 | _aKoller, Erich | |
| 700 | 1 | _aDean, Nicholas M | |
| 700 | 1 | _aAndreeff, Michael | |
| 773 | 0 |
_tCell cycle (Georgetown, Tex.) _gvol. 5 _gno. 19 _gp. 2223-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4161/cc.5.19.3255 _zAvailable from publisher's website |
| 999 |
_c16551661 _d16551661 |
||